Bita Fakhri

MD MPH

Hematologist-oncologist
Lymphoma researcher, avid hiker and art enthusiast

About me

Dr. Bita Fakhri is a hematologist-oncologist who cares for adults with conditions such as Hodgkin's lymphoma, non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL), a blood and bone marrow cancer. She sees many patients who are receiving cellular therapies – which use modified human cells to help the immune system fight cancer – or blood and bone marrow transplants.

In her research, Fakhri focuses on novel approaches to treating lymphoma. She primarily studies targeted agents for CLL and cellular therapies for all types of lymphoma.

After earning her medical degree at Iran University of Medical Sciences, Fakhri earned a master of public health degree, focused on epidemiology and biostatistics, from the Yale School of Public Health. She completed a residency in internal medicine at Boston Medical Center, followed by a fellowship in hematology and oncology at the Washington University School of Medicine in St. Louis. She also has a graduate certificate in clinical investigation from the Washington University School of Medicine in St. Louis.

Fakhri is a member of the American Society of Hematology, American Society of Clinical Oncology and American Society for Transplantation and Cellular Therapy.
  • Education

    Iran University of Medical Sciences, 2009

    Yale School of Public Health, MPH, 2011

  • Residencies

    Boston Medical Center, Internal Medicine, 2015

  • Fellowship

    Washington University School of Medicine in St. Louis, Hematology and Oncology, 2018

My patients' strength, perspective and resilience never cease to inspire and amaze me.

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

Decorative Caduceus

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell T...

A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cel...

Recruiting

Decorative Caduceus

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic...

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the reco...

Recruiting

Decorative Caduceus

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

Recruiting

Share